IN THE AMOUNT OF SDR 21.8 MILLION (US$30 MILLION EQUIVALENT) WITH AN ADDITIONAL GRANT FROM THE GLOBAL FINANCING FACILITY (GFF) IN THE AMOUNT OF US$ 10 MILLION TO THE DEMOCRATIC REPUBLIC OF CONGO FOR A HUMAN DEVELOPMENT SYSTEMS STRENGTHENING PROJECT
Project Paper to provide an additional grant for: Human Development Systems Strengthening Project (HDSSP)(P145965, H9360)
временное руководство, 13 мая 2020 г.
Целью настоящего документа является предоставле- ние временных рекомендаций по биологической без- опасности в лабораторных усл...виях, которые следует соблюдать при исследовании клинических образцов пациентов, подпадающих под определение случаев ин- фицирования новым патогеном, выявленным в Ухане, Китай, то есть коронавирусным заболеванием 2019 г. COVID-19.
more
Will COVID-19 vaccines be safe? Will all the COVID-19 candidate vaccines be successful? What are the different phases a vaccine must go through to be approved? This document provides responses to the most frequently asked questions about candidate vaccines and access to COVID-19 vaccination.
the Principles for Dose-Sharing provide a framework for higher-income economies to make additional volumes secured via bilateral deals available through the Facility primarily to AMC participants, on an equitable basis. These principles outline that such doses must be safe and effective, available a...s early as possible and should be available in substantive volumes as early as possible in 2021 to enable rapid and flexible deployment by the Facility – supporting the overall goal of equitable access.
18 Dec 2020
more
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
This presentation presents the issues we confront in deciding how to communicate to the public that COVID-19 vaccine recommendations reflect the state of scientific knowledge.
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
11 august 2022, updated version
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.
Access to controlled medicines. 3rd edition